#19: TheMachine: Altus Pharmaceuticals Announces Achievement of Primary Endpoint in Phase 3 Efficacy Trial of Trizytek for Cystic Fibrosis Patients with Pancreatic Insufficiency
Investor Conference Call Scheduled for 4:30 PM ET on August 11, 2008
... |
August 20, 2008
01:11:22 AM |
#18: TheMachine: Altus Pharmaceuticals Announces Webcast of Presentation at Collins Stewart Growth Conference
Altus Pharmaceuticals Inc. (NASDAQ: ALTU), announced today that... |
July 9, 2008
12:10:35 PM |
#17: NewsBot: Altus Pharmaceuticals to Present at the Cowen and Company 28th Annual Healthcare Conference
Altus Pharmaceuticals to Present at the Cowen and Company 28th Annual Healthcare... |
April 13, 2008
03:50:05 PM |
#16: NewsBot: ALTU News Altus Pharmaceuticals Reports Fourth Quarter and Year End 2006 Financial Results and Provides Milestones for 2007
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Altus Pharmaceuticals Inc. (NASDAQ: ALTU), a... |
March 12, 2007
04:47:00 AM |
#15: NewsBot: ALTU News Altus Pharmaceuticals to Webcast Presentation at the Cowen and Company 27th Annual Health Care Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Altus Pharmaceuticals Inc. (NASDAQ: ALTU) today... |
March 9, 2007
06:36:00 AM |
#14: NewsBot: ALTU News Altus Pharmaceuticals to Host Fourth Quarter and Year End Investor Conference Call on March 12, 2007
CAMBRIDGE, Mass.--(BUSINESS WIRE)--On Monday, March 12, 2007 before the market... |
March 6, 2007
12:09:00 PM |
#13: NewsBot: ALTU News Altus Pharmaceuticals Enters into Exclusive Strategic Collaboration with Genentech to Develop and Commercialize Products for Growth Hormone Deficient Patients
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Altus Pharmaceuticals Inc. (NASDAQ: ALTU)... |
December 20, 2006
05:14:00 AM |
#12: NewsBot: ALTU News Altus Pharmaceuticals Appoints Bruce A. Leicher General Counsel
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Altus Pharmaceuticals Inc. (NASDAQ: ALTU), a... |
December 19, 2006
05:13:00 AM |
#11: NewsBot: ALTU News Altus Pharmaceuticals Appoints Shire Executive David Pendergast to Board of Directors
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Altus Pharmaceuticals Inc. (NASDAQ: ALTU), a... |
November 21, 2006
05:30:00 AM |
#10: NewsBot: ALTU News Altus Pharmaceuticals Reports Positive ALTU-237 Pre-Clinical Data for Reducing Hyperoxaluria, a Precusor to Kidney Stone Formation
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Altus Pharmaceuticals Inc. (NASDAQ: ALTU), a... |
November 20, 2006
05:30:00 AM |
#9: NewsBot: ALTU News Altus Pharmaceuticals Secures ALTU-135 Commercial Manufacturer
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Altus Pharmaceuticals Inc. (NASDAQ: ALTU), a... |
November 17, 2006
06:00:00 AM |
#8: NewsBot: ALTU News Altus Pharmaceuticals Plans to Initiate ALTU-135 Phase III Trial in the Second Quarter of 2007
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Altus Pharmaceuticals Inc. (NASDAQ: ALTU), a... |
November 15, 2006
04:03:00 AM |
#7: NewsBot: ALTU News Altus Pharmaceuticals Reports Third Quarter Financial Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Altus Pharmaceuticals Inc. (NASDAQ: ALTU), a... |
November 15, 2006
04:01:00 AM |
#6: NewsBot: ALTU News Altus Pharmaceuticals Announces Presentation of ALTU-238 Phase II Data at International Congress of Growth Hormone and Insulin-Like Growth Factor Research Societies
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Altus Pharmaceuticals Inc. (NASDAQ: ALTU), a... |
November 13, 2006
05:32:00 AM |
#5: NewsBot: ALTU News Altus Pharmaceuticals Secures Phase III Manufacturer, Althea Technologies, for ALTU-238
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aug. 21, 2006--Altus Pharmaceuticals Inc.... |
August 21, 2006
01:10:00 PM |
| 
| 
| 
| 
| 
| 
